Peginterferon alfa-2a
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Myelofibrosis
Conditions
Myelofibrosis
Trial Timeline
Jan 1, 2013 → Jun 1, 2017
NCT ID
NCT01758588About Peginterferon alfa-2a
Peginterferon alfa-2a is a phase 2 stage product being developed by Merck for Myelofibrosis. The current trial status is terminated. This product is registered under clinical trial identifier NCT01758588. Target conditions include Myelofibrosis.
What happened to similar drugs?
2 of 19 similar drugs in Myelofibrosis were approved
Approved (2) Terminated (3) Active (14)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01758588 | Phase 2 | Terminated |
Competing Products
20 competing products in Myelofibrosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Ruxolitinib + Abemaciclib | Eli Lilly | Phase 1 | 36 |
| Nusivertib + Ruxolitinib + Momelotinib | Sumitomo Pharma | Phase 1/2 | 39 |
| Ruxolitinib + Navitoclax | AbbVie | Phase 2 | 35 |
| ABBV-744 + Navitoclax + Ruxolitinib | AbbVie | Phase 1 | 33 |
| Placebo for Navitoclax + Ruxolitinib + Navitoclax | AbbVie | Phase 3 | 40 |
| Mivebresib + Navitoclax + Ruxolitinib | AbbVie | Phase 1 | 21 |
| Navitoclax + Venetoclax | AbbVie | Pre-clinical | 26 |
| Navitoclax + Ruxolitinib + Best Available Therapy (BAT) | AbbVie | Phase 3 | 44 |
| NS-018 + Best Available Therapy | Nippon Shinyaku | Phase 2 | 27 |
| AZD1480 | AstraZeneca | Phase 1 | 29 |
| Bomedemstat | Merck | Phase 2 | 31 |
| Bomedemstat | Merck | Phase 1/2 | 32 |
| MBG453 + NIS793 + Spartalizumab + Decitabine | Novartis | Phase 1 | 21 |
| PIM447 + Ruxolitinib + LEE011 | Novartis | Phase 1 | 29 |
| LDE225 + INC424 | Novartis | Phase 1/2 | 32 |
| Imatinib mesylate | Novartis | Phase 2 | 35 |
| Ruxolitinib + Siremadlin + Crizanlizumab + Sabatolimab + Rineterkib + NIS793 | Novartis | Phase 1/2 | 24 |
| Ruxolitinib + Ruxolitinib Placebo | Novartis | Phase 3 | 32 |
| Ruxolitinib | Novartis | Pre-clinical | 30 |
| ruxolitinib | Novartis | Phase 2 | 35 |